Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rNAPc2 in hospitalized COVID-19
NCT04655586Phase 3Completed
- Sponsor
- Oruka Therapeutics
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of recombinant nematode anticoagulant protein c2 in coronavirus disease 2019 (COVID-19), sponsored by Oruka Therapeutics. Started Dec 2020; status: completed.
02
Drugs
recombinant nematode anticoagulant protein c2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04655586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655586.